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Background: Elevated follicle stimulating hormone (FSH) is associated with poor vaginal oocyte retrieval (VOR)
outcomes and cycle cancellations but intercycle variability in basal FSH reportedly does not predict ovarian response.
Methods: We conducted a retrospective cohort study of basal FSH (n = 15573 cycles) in couples (n = 9132) who
initiated IVF cycle(s) with basal estradiol (E2) <100 pg/mL between 2002 and 2014 to reevaluate this hypothesis.
The most recent (current) FSH, maximum FSH (Max FSH) and prior cycle maximum basal FSH (PMax FSH) were
computed for each cycle. Metaphase II (MII) oocyte counts were modeled by age, stimulation type, prior peak E2 level,
prior MII count, Max FSH, PMax FSH and current FSH. Antral follicle counts, pregnancy, clinical pregnancy and live birth
rates were modeled as secondary outcomes.
Results: Max FSH level distinguished completed cycles from cancelled cycles better than PMax FSH or current FSH
(AUC of 0.72, 0.71 and 0.61, respectively, p < 0.001). Fewer MIIs were retrieved (5.7 ± 3.8) in cycles with Max FSH >13
mIU/mL (n = 1475) than those with ≤13 mIU/mL (n = 11978) (11.6 ± 7.1) (p < 0.001). Max FSH was a better predictor of
MII count than PMax FSH or current FSH after controlling for age, stimulation type, prior peak E2 level and prior MII
count.
Additional MIIs were retrieved on average in cycles with PMax FSH >13 mIU/mL (n = 1930) whose current FSH was
≤13 mIU/ml rather than >13 mIU/ml (p < 0.01) after controlling for age, cycle number and stimulation type. However,
no improvement in pregnancy or live birth rate was detected.
Conclusions: Max FSH is the best FSH-based predictor of ovarian reserve. Retrieval benefits from waiting for a "better"
month appear to exist but are limited.
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Elevated follicle stimulating hormone (FSH) measurements are associated with more frequent in vitro fertilization
(IVF) cycle cancellations and fewer oocytes (eggs) being retrieved. It has been thought that a patient with an
elevated FSH in the past would not have more oocytes retrieved if her FSH decreased in a subsequent cycle rather
than remain elevated. We questioned this belief in a study of over 9132 couples who used IVF between 2002 and
2014. We assessed the effect of a patient's set of FSH measurements on her future outcomes, carefully focusing on
1930 cycles with a previously elevated FSH.
We found that the patient's highest FSH was the best predictor of cycle cancellations and the number of oocytes
retrieved. However, even after controlling for the highest FSH, a patient was predicted to obtain slightly more
oocytes at retrieval if her FSH decreased. However, we did not detect any improvement in pregnancy or live birth
rates.
Retrieval benefits from waiting for a "better" month appear to exist but are limited.
Capsule: Highest historical FSH levels better predict cancellations and VOR counts than cycle-specific FSH, but waiting
for a cycle with lower basal FSH still enhances retrieval outcomes.Background
Controlled ovarian hyperstimulation (COH) is an essen-
tial tool in assisted reproduction, but patient response
varies significantly [1, 2]. Ovarian response to gonado-
tropin stimulation is negatively correlated with basal
(early follicular phase) follicle stimulating hormone
(FSH) levels [3]. FSH levels correlate with vaginal oocyte
retrieval (VOR) outcomes independently of age [4, 5], al-
though their impact on fertilization or implantation rates
is at best limited [6–11]. Because of this association,
ovarian reserve testing has routinely included basal FSH
levels for the past 20 years [12–16].
Precise interpretation of basal FSH measurements has
remained elusive. The treatment of patients with dimin-
ished ovarian reserve (DOR) remains a persistent chal-
lenge [17]. Because collection of additional oocytes (up
to ~15) is associated with an increased embryo count
and hence live birth rate [18, 19], all avenues for opti-
mizing VOR outcomes, including the timing of ART cy-
cles, are of substantial clinical interest.
Many clinicians have declined to proceed with an IVF
cycle following the detection of an elevated basal FSH
out of concern for a poor VOR outcome [11, 20, 21]. In-
creased cycle cancellation rates have been reported in
patients with an elevated basal FSH [22].
However, a decision to cancel based on an elevated
FSH implicitly assumes that a patient who waits for a
"better" month with lower basal FSH levels will have im-
proved VOR outcomes. The existence of a "better"
month has never before been rigorously scrutinized, in
part because others have claimed that it does not exist
[23, 24]. The possible importance of the most recent
basal FSH has been called into question by studies dem-
onstrating that a patient's most elevated FSH was at least
as good a predictor of ovarian response as the basal FSH
in an individual cycle [22–25] and that patients with
prior elevations in basal FSH experienced decreasedoocyte yield in a subsequent cycle compared to those
with normal FSH levels [26].These studies had reported
that intercycle variability in basal FSH did not predict
ovarian response and could not be used to select an op-
timal cycle [23]. They also suggested that inclusion of
cycle-specific basal FSH conveyed no additional predict-
ive information on ovarian response than using the high-
est FSH alone [24].
Nonetheless, the high cycle-to-cycle fluctuation of
FSH and its association with VOR outcomes leaves open
the tantalizing prospect that an ART cycle initiated with
a lower basal FSH measurement might be associated
with a higher expected VOR outcome. This study sought
to challenge the dogma that waiting for a "better" month
with improved basal FSH did not enhance outcomes, i.e.
no other FSH measurements had predictive value in
conjunction with the highest FSH. By representing all of
a patient's previous and present FSH elevations as one
parameter, the maximum FSH, we could reevaluate
whether it predicted VOR better than the current cycle
basal FSH. If so, we could directly control for the max-
imum FSH and model the role of the potentially modifi-
able current basal FSH on VOR outcomes to give a
precise estimate of the benefits associated with waiting
for a lower FSH.
Methods
Patients
A single-center retrospective cohort study was per-
formed on patients who initiated IVF cycles between
January 2002 and March 2014. Study groups were identi-
fied from an electronic medical records database accord-
ing to the patient’s basal FSH history.
Treatment protocol
IVF stimulation cycles and hormonal adjustments were
performed according to standard clinical practice [11].
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one of three different protocols determined by clinician
preference: antagonist (ganirelix acetate, Antagon®, Or-
ganon USA Inc., Roseland, NJ or cetrorelix acetate,
Cetrotide®, EMD Serono, Rockland, MA); downregula-
tion (leuprolide acetate, Lupron®, AbbVie Inc., North
Chicago, IL); or microflare (leuprolide acetate, Lupron®,
AbbVie Inc., North Chicago, IL). In general, downregula-
tion and antagonist protocols were used in most pa-
tients, with the antagonist protocol used specifically in
potential hyperresponders and the microflare protocol in
poor responders. Total gonadotropin dose was calcu-
lated for each patient in IU.
Final oocyte maturation was induced with 6500 IU re-
combinant hCG alone (Ovidrel®, EMD Serono, Rockland,
MA) or, in patients with strong ovarian response or at
risk for ovarian hyperstimulation syndrome (OHSS)
undergoing an antagonist protocol, with 40 IU of leupro-
lide acetate together with 1000 IU of hCG (Novarel®,
Ferring Pharmaceuticals, Parsippany, NJ) following con-
firmation of ≥2 mature follicles ≥18 mm by ultrasound.
Vaginal oocyte retrieval (VOR) was performed under
transvaginal ultrasound guidance 36 h later.
Clinical management
Basal FSH measurements were routinely taken on Day 3
of the patient's menstrual cycle. For patients who lacked
measurements specifically on Day 3, Day 2 or Day 1
measurements were used as substitutes, in that order,
for both basal FSH and estradiol (E2) (these time points
are collectively referred to as "basal" henceforth). FSH
measurements with a same-day E2 ≥ 100 pg/mL (within
24 h of FSH measurement) were excluded from the study.
Cycle cancellation was recommended when patients
had ≤4 mature follicles ≥14 mm and/or >50 % fewer fol-
licles developing than at the same point in a recent
(≤1 year prior) cycle; no growing follicles observed dur-
ing COH in a time frame of 5-6 days; or no increase in
E2 level between 2 monitoring days at any point during
ovarian stimulation.
For each multi-cycle patient at each IVF cycle, the
fluctuations in basal FSH were used to calculate 3 pa-
rameters: current FSH, maximum FSH (Max FSH) and
previous maximum FSH (PMax FSH). "Current FSH" de-
notes the basal FSH level at the beginning of the given
ART cycle. That is, the "current FSH" of a patient with
respect to IVF cycle 3 is her basal FSH at the beginning
of cycle 3. "Maximum FSH" denotes the maximum of all
basal FSH measurements up to and including the given
cycle, including cancelled or non-IVF cycles. "Previous
maximum" FSH denotes the maximum of all basal FSH
measurements prior to the cycle (i.e. excluding any
current cycle measurements), including cancelled or
non-IVF cycles. Sample calculations of FSH parametersfor a set of hypothetical patients are detailed in Table 1.
E2 levels on the day of ovulatory trigger were recorded
as "E2 surge". A basal FSH level was considered elevated
if it exceeded 13 mIU/mL, according to our standard
clinical practice [11].
AMH levels were extracted, when available, and were
considered to be associated with a given IVF cycle if they
were made within the year prior to the ovulatory trigger
day of the cycle. For patients with multiple such mea-
surements, the most recent value was used.
Patients were stratified by SART age groups [27] ac-
cording to the date at which the IVF cycle was initiated:
A (≤35 years old (yo)), B (35-38 yo), C (38-41 yo), D
(41-43 yo) and E (>43 yo). The time elapsed between the
Max FSH measurement and the current FSH was binned
as zero months (0-15 d), one month (15-45 d), two
months (45-75 d), 2 to 6 months (75-180 d) and more
than 6 months (>180 d). For patients whose entire IVF
treatment was at our clinic, the IVF cycle number was
recorded as 1, 2, 3, 4 or 5+. Number of embryos trans-
ferred was recorded was 1, 2, 3, 4 or 5+.
History of prior pregnancy was typically recorded for
each patient at intake. Primarily infertility was defined as
never having been pregnant at the time of presentation
(first IVF treatment). Patients with any prior history of
pregnancy at presentation were considered to have sec-
ondary infertility.
For patients whose entire infertility treatment was per-
formed at the study's clinic, the time in days between the
present IVF cycle and the first cycle (non-IVF or IVF) was
calculated. The time in days between the present IVF cycle
and the first IVF cycle was also computed.
Assays
Serum FSH levels were quantitatively assessed by solid-
phase, two-site competitive chemiluminescent immuno-
metric assay (Immulite 2000, Siemens, Germany) with
an analytical sensitivity of 0.1 mIU/mL and an intra-
assay coefficient of variation 2.9–4.2 % for values
between 6.8 and 103 mIU/mL. Serum E2 levels were
quantitatively assessed by solid-phase enzyme-labeled
chemiluminescent competitive immunoassay (Immulite
2000, Siemens) with an analytical sensitivity of 15 pg/
mL, reportable range up to 2000 pg/mL, and an intra-
assay coefficient of variation 4.3–9.9 % for values be-
tween 89 and 1800 pg/mL. Serum anti-müllerian hor-
mone (AMH) levels were measured using dual
monoclonal antibodies in a chemiluminescent immuno-
assay (Quest Diagnostics, USA) with an analytical sensi-
tivity of 0.03 ng/mL. Human chorionic gonadotropin
(hCG) were quantitatively assessed by solid-phase, two-
site competitive chemiluminescent immunometric assay
(Immulite 2000, Siemens, Germany) with an analytical
sensitivity of 0.4 mIU/mL, reportable range up to 5000
Table 1 Sample patient FSH parameters and calculation of Max, PMax and current FSH
Consider a set of hypothetical patients whose basal FSH measurements in cycles 1-4 are as shown. Current FSH denotes the basal FSH level at the beginning of the given
cycle. Maximum (Max) FSH denotes the maximum of all basal FSH measurements up to and including the given cycle, including cancelled or non-IVF cycles. Previous
maximum (PMax) FSH denotes the maximum of all basal FSH measurements prior to the cycle, including cancelled or non-IVF cycles
We will first calculate these values for cycle 3. For patient 1, the current FSH is also the Max FSH (12 mIU/mL). Because the current (most recent) cycle FSH is
never considered when calculating PMax, the PMax FSH for patient 1 is the maximum over all previous cycles (9 mIU/mL). For patients 2 and 3, the Max FSH was
measured previously and is the same as the PMax FSH. Note that the FSH measurements from cycle 4 play no role in the calculation of FSH parameters for cycle 3
Now consider the same calculations for cycle 4. For patient 1, the new Max FSH is 14 mIU/mL, while PMax FSH is 12 mIU/mL. Note that PMax FSH in the next
cycle is the same as Max FSH in the previous cycle. For patients 2 and 3, Max FSH are now from the current cycle (16 and 17 mIU/mL, respectively) while PMax
FSH remains 15 mIU/mL
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6.6 % for values between 6.5 and 3,120 mIU/mL. Assays
were performed on the same equipment through patient
cycles.
Outcomes
Primary outcome variables were cycle cancellation and
metaphase II (MII) oocyte counts. Secondary outcomes
were basal antral follicle count (BAFC), pregnancy rates
(PRs), clinical PRs and live birth rates (LBRs). A preg-
nancy was defined as having a serum hCG level exceeding
5 mIU/mL. A clinical pregnancy was defined as the identi-
fication of a uterine gestational sac 23-27 days after trans-
fer or 9 days after a positive pregnancy test. LBR was
defined as the percentage of all cycles that led to live birth.
Cycle cancellations were predicted based on Max FSH,
PMax FSH or current FSH values using a logistic regres-
sion model and performance scored with a receiver oper-
ating characteristic (ROC) curve. For completed cycles, a
Poisson regression generalized estimating equations (GEE)
model was created predicting BAFC and MII count by age
group, cycle number, stimulation protocol, previous MIIcount, previous and current cycle E2 surge level, previous
and current cycle total gonadotropin dosage, AMH levels,
Max FSH, PMax FSH, current FSH and time since Max
FSH. PR, clinical PR and LBR were modeled with a GEE
binomial model by the same parameters as MII count as
well as number of embryos transferred, insemination type
(conventional insemination vs intracytoplasmic sperm in-
jection (ICSI)) and day of embryo transfer (ET).
Statistical analyses
Statistical analysis was performed in the R programming
language [28]. All two-group comparisons were made by
two-sided unpaired T-test. Probability density estimates
of FSH parameters were computed with the "density"
function in R with default settings. Distributions of
cancelled and completed cycle FSH parameters were
compared by Kolmogorov-Smirnov statistic. Receiver op-
erating characteristic analysis was performed using the
pROC package in R [29]. ROC confidence intervals and
comparison between ROC models were calculated using
the DeLong method [30]. GEE models were constructed
using the R package geepack with an exchangeable
Patient Age Distribution



























































Fig. 1 Patient Population Parameters. Histograms of patient a) age distribution and b) Max FSH distribution. Cycles with Max FSH >13 mIU/mL are
shown in red. c) Quantiles of time since Max FSH measurement. d) Table of number of initiated and completed cycles
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dered by cycle number for each patient. Significant terms
from univariate regression models were tested in combin-
ation for significance within multivariate models. GEE
models were compared using the correlation information
criterion (CIC), calculated with the QIC function of the R
package MESS [32]. Model significance was tested by chi-
square of Wald statistic.
Ethics, consent and permissions
This research was approved by the Western Institutional
Review Board (WIRB). Because of its retrospective,
anonymized, aggregated nature, no informed consent
was required.
Results
A total of 9132 patients initiated 15573 IVF cycles be-
tween 2002 and 2014. Patients were 37.2 ±4.7 years
old (yo) and had a Max FSH of 9.18 ±4.27 mIU/mL
(Fig. 1a-b). Of the completed cycles (n=13453), 57.2 %(n=7698) were ICSI, 40.5 % (n=5448) were conventional
insemination, and 2.3 % (n=307) were split ICSI and
conventional insemination (Table 2, Additional file 1:
Table S1). Of the patients with a complete intake history
(n=6926), 50.6 % (n=3504) had a diagnosis of primary
infertility, while 49.4 % (n=3422) had a diagnosis of sec-
ondary infertility (Table 2). The most common causes of
infertility across these cycles were male-factor (19.8 %),
diminished ovarian reserve (18.2 %), idiopathic (18.2 %)
and tubal factor (12.1 %) (Table 2).
For patients (n=4025) whose entire infertility treat-
ment (n=7195 cycles) was performed at our clinic, IVF
cycles were initiated a median of 276 days (50 % within
138-695 days) following the initial non-IVF cycle and a
median of the 177 days (50 % within 88-541 days) fol-
lowing the initial IVF cycle.
A majority of patients underwent 1 or 2 cycles (57 %
(n=5180) and 26 % (n=2402), respectively). Others under-
went more cycles, up to a maximum of 13 (0.02 % (n=2)).
Fourteen percent of cycles (n=2120) were cancelled prior
Table 2 Characteristics of cycles. Cycles were divided by age
group, cycle status, cycle number, insemination type, stimulation
type, infertility cause, ET day and number of embryos transferred.
The number of cycles in each group was noted
Grouping Cycles %





Cycle Status Completed 13,453 86.4
Cancelled 2120 13.6





Insemination Type Conventional 5448 40.5
ICSI 7698 57.2
Both 307 2.3
Stimulation Type Antagonist 8023 51.5
Down Regulation 5005 32.1
Microflare 2545 16.3













Single Woman 114 0.7





Table 2 Characteristics of cycles. Cycles were divided by age
group, cycle status, cycle number, insemination type, stimulation
type, infertility cause, ET day and number of embryos transferred.
The number of cycles in each group was noted (Continued)





DOR: diminished ovarian reserve
PCO: polycystic ovaries
RPL: recurrent pregnancy loss
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(n=1323 of 1554) were in patients with a normal current
FSH (≤13 mIU/mL) and 64 % (n=1347 of 2120) were in
patients with Max FSH ≤13 mIU/mL (i.e. who had never
previously experienced an abnormal FSH). Together, 21 %
of cancelled cycles were in patients whose FSH was normal
at the time of the cycle but abnormal in the past (Fig. 2a).
Of patients with Max FSH >13 mIU/mL at the begin-
ning of their first IVF cycle (n=572), 40.7 % (n=233) ul-
timately underwent multiple IVF cycles. Of patients with
current FSH >13 mIU/mL at the start of their first IVF
cycle (n=186), 38.2 % (n=71) ultimately underwent multiple
IVF cycles. In more than 50 % of cycles, a patient's Max
FSH was observed within the previous 2 months (Fig. 1c).
Max FSH is the best FSH-based predictor of cancellations
The distribution of Max FSH levels differed more be-
tween completed and cancelled cycles than did the dis-
tribution of either PMax FSH or current FSH level
between completed and cancelled cycles (0.35 vs 0.34 or
0.19 Kolmogorov-Smirnov statistic, respectively, p<0.001
for all comparisons, larger numbers represent greater dif-
ferences) (Fig. 2c). ROC analysis was performed to deter-
mine the FSH parameters that best predicted cycle
cancellations. Max FSH predicted cycle cancellation better
than either PMax FSH or current FSH (AUC of 0.72
[0.71–0.74 95 % CI], 0.71 [0.70–0.72]] and 0.61 [0.59–0.62],
respectively) (Fig. 2b). The AUC of the Max FSH prediction
was significantly better than either the PMax FSH or
current FSH prediction (p<0.001), and the PMax FSH pre-
diction AUC was significantly better than the current FSH
prediction (p<0.001). Collectively, Max FSH values better
distinguished cancelled from completed cycles than in
PMax or current FSH and thus were better predictors of
cancellations than either other parameter.
Max FSH correlates with VOR across age groups better
than current FSH
Current FSH was negatively correlated with VOR
counts when controlled for age group (Fig. 3a). Fewer
MIIs (5.5 ±3.5) were retrieved in cycles with current
p<0.001 for all comparisons by 
Chi-square test
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Current FSH Cancelled Cycles
PMax FSH Completed Cycles
PMax FSH Cancelled Cycles
Max FSH Completed Cycles





AUC=0.72, 0.71 and 0.61 for Max FSH, 

































Fig. 2 Max FSH predicts cycle cancellations better than current FSH. a Number of completed and cancelled cycles with Max FSH and current FSH
data, grouped by Max and current FSH elevation status. + indicates true and - indicates false. b Receiver operating characteristic (ROC) curve for
model prediction of cycle cancellation using Max FSH (red), PMax FSH (blue), current FSH (black) or null hypothesis (grey). c Distribution of Max
FSH, PMax FSH and current FSH in completed and cancelled cycles. IVF cycles were divided into the subset of completed and cancelled ones and
the distribution of their respective Max FSH, PMax FSH and current FSH levels was plotted in red, blue and black, respectively. Completed cycles
were plotted in solid lines and cancelled cycles in dashed lines. The Kolmogorov-Smirnov statistic between the distribution parameters for completed
and cancelled cycles is noted to the right of each bracketed pair (see Methods for details)
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mL (n=8044) (10.4 ±7.1) (p<0.001) (Additional file 1:
Table S1). Max FSH was also negatively correlated with
VOR counts when controlled for age group (Fig. 3b).
Fewer MIIs (5.7 ±3.8) were retrieved in cycles with
Max FSH >13 mIU/mL (n=1475) than those with Max
FSH ≤13 mIU/mL (n=11978) (11.6 ±7.1) (p <0.001)
(Additional file 1: Table S1). Fewer MIIs were retrieved in
cycles with PMax FSH >13 mIU/mL (n=1262) (5.7 ±3.8)
than those with ≤13 mIU/mL (n=11575) (11.5 ±7.1)
(p<0.001) (Additional file 1: Table S1).
VOR counts in cycles with Max FSH ≤13 mIU/mL
were greater than in cycles with only current FSH ≤13mIU/mL in all but the <35 yo age group by approxi-
mately one MII-stage oocyte (p<0.001 for age groups B-
E, Additional file 1: Table S1). Thus, cycles in patients
over 35 years old yielded more MII oocytes when all
previous and current FSH levels were normal than those
in which only the current FSH was known to be normal.
Multiple clinical parameters are individually associated
with BAFC and MII
The individual (univariate) association of cycle parame-
ters with BAFC and MII count was explored with a
GEE model controlling for patient and cycle number








































Fig. 3 Max FSH and current FSH negatively correlate with MII retrievals. Average number of MII-stage oocytes retrieved, binned both by age group
and by either a) current FSH level or b) Max FSH
Table 3 Individual association of cycle parameters with BAFC and MII count
BAFC MII Count
Parameter Compared With Odds Ratio 95 % CI Sig. Odds Ratio 95 % CI Sig.
Age Group B Age Group A 0.80 [0.75,0.84] *** 0.84 [0.79,0.89] ***
Age Group C Age Group A 0.68 [0.64,0.72] *** 0.73 [0.69,0.77] ***
Age Group D Age Group A 0.60 [0.56,0.64] *** 0.64 [0.60,0.69] ***
Age Group E Age Group A 0.54 [0.51,0.58] *** 0.53 [0.48,0.58] ***
Downregulation Protocol Antagonist Protocol 1.37 [1.28,1.47] *** 1.16 [1.09,1.23] ***
Microflare Protocol Antagonist Protocol 0.70 [0.67,0.73] *** 0.72 [0.68,0.76] ***
IVF Cycle 2 IVF Cycle 1 1.00 [0.96,1.04] 0.94 [0.91,0.97] ***
IVF Cycle 3 IVF Cycle 1 0.99 [0.93,1.06] 0.96 [0.91,1.01]
IVF Cycle 4 IVF Cycle 1 0.97 [0.90,1.05] 0.98 [0.91,1.05]
IVF Cycle 5+ IVF Cycle 1 0.95 [0.86,1.06] 0.88 [0.79,1.00] *
Previous MII Count Per Oocyte 1.04 [1.03,1.04] *** 1.04 [1.04,1.05] ***
E2 Surge Level Per 1000 pg/mL 1.21 [1.19,1.23] *** 1.40 [1.37,1.42] ***
Previous E2 Surge Level Per 1000 pg/mL 1.22 [1.18,1.27] *** 1.28 [1.24,1.32] ***
Total Gonadotropin Dosage Per 1000 IU 0.77 [0.75,0.78] *** 0.82 [0.81,0.83] ***
Previous Total Gonadotropin Dosage Per 1000 IU 0.80 [0.78,0.83] *** 0.86 [0.84,0.88] ***
AMH Per 1 ng/mL 1.07 [1.04,1.10] *** 1.09 [1.05,1.12] ***
Max FSH Per 1 mIU/mL 0.93 [0.93,0.94] *** 0.91 [0.91,0.92] ***
PMax FSH Per 1 mIU/mL 0.94 [0.93,0.95] *** 0.92 [0.91,0.93] ***
Current FSH Per 1 mIU/mL 0.98 [0.97,0.98] *** 0.95 [0.94,0.96] ***
Max FSH Observed 1 Month Ago 0 Months Ago 0.98 [0.92,1.04] 1.11 [1.05,1.17] ***
Max FSH Observed 2 Months Ago 0 Months Ago 0.98 [0.91,1.06] 1.06 [0.99,1.14]
Max FSH Observed 2-6 Months Ago 0 Months Ago 0.97 [0.92,1.02] 1.06 [1.00,1.11]
Max FSH Observed >6 Months Ago 0 Months Ago 1.01 [0.95,1.07] 1.07 [1.01,1.13] *
A GEE model controlling for patient and cycle number was constructed to test the association of multiple clinical parameters with BAFC or MII count. Association
was noted as odds ratio (OR) with 95 % confidence intervals. Model significance was noted as *** (p<0.001) or * (p<0.05)
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previous and current cycle total gonadotropin dosage,
and AMH levels were associated with both BAFC and
MII count (all p<0.001) (Table 3). IVF cycle number was
associated with MII count but not BAFC (p<0.05)
(Table 3).
Max FSH, PMax FSH and current FSH were associ-
ated with BAFC and MII count. An elevation of
1 mIU/mL in Max FSH was associated with a more
decreased MII count than a comparable elevation of
PMax FSH or current FSH (odds ratio (OR) 0.91 vs
0.92 and 0.95, p<0.05) (Table 3). Time since Max FSH
was not associated with BAFC. However, patients
whose Max FSH was measured in the previous month
or >6 months experienced increased MII counts com-
pared with patients whose Max FSH was made in
the same month as their IVF cycle (OR 1.11 and 1.07,
respectively) (Table 3).Max FSH and current FSH together optimize MII
predictions in a combined model
The non-FSH parameters individually associated with
MII count were used to construct a combined (multi-
variate) model of MII count. Age group, cycle number,
stimulation type, previous cycle MII count, previous
cycle E2 surge level and previous cycle total gonado-
tropin dosage (n=1220 cycles in 909 patients) were
tested in combination for an association with MII count.
Age group, stimulation type, previous cycle MII count,
and previous cycle E2 surge level remained associated
with MII count (CIC score 10.2, p<0.001 for each par-
ameter). There was no significant association between
cycle number or previous cycle total gonadotropin dose
and MII count.
Current FSH, Max FSH and PMax FSH were next
added to the combined model. Each parameter remained
individually associated with MII count (p<0.001).
Remaining variability in MII count was better explained
by Max FSH than PMax FSH or current FSH (11.9 vs
11.8 or 11.3 CIC score, respectively, larger CIC is better).
Inclusion of current FSH into the combined model
with Max FSH further improved the model (12.8 CIC
score, p<0.05). The combined model estimated MII
counts as:log MII countð Þ ¼ 2:25−
(
0 if ≤35 yo
0:02 if 35; 38½ Þ yo
0:12 if 38; 41½ Þ yo
0:17 if 41; 43½ Þ yo






 Surge E2 Prev 1000 pg=mLð Þ−0:029 MaxFSH mIU=mLðFor example, a typical patient (38.3 yo, antagonist
cycle, previous cycle MII count of 8, previous cycle E2
surge 1560 pg/mL, Max FSH 8.7 mIU/mL, current FSH
6.1 mIU/mL) is predicted to obtain 8.1 MII oocytes in
her cycle on average.
Role of AMH
Because AMH was assessed in relatively few cycles
(<11 %), the combined model of MII count did not in-
corporate AMH levels. However, in a separate multivariate
model of MII count in patients with AMH assessments
(n= 546 cycles in 450 patients), Max FSH significantly im-
proved predictions when combined with age and AMH
data compared with using age and AMH alone (p<0.001).
Use of current FSH values in combination with age, AMH
and Max FSH significantly improved the MII prediction
compared with age, AMH and Max FSH alone (p<0.05),
suggesting that AMH measurements are best interpreted
in conjunction with both current and Max FSH levels.
Current FSH improves MII prediction in cycles with
elevated PMax FSH
The effect of current FSH was explored in patients with
a previously elevated FSH at any point (i.e. PMax FSH >13
mIU/mL). Significantly fewer MII oocytes were retrieved
(4.9 ±3.16, n=166) in cycles with a current FSH >13 mIU/
mL (i.e. FSH was elevated this cycle and in the past) than
in cycles with current FSH ≤13 mIU/mL (i.e. FSH was ele-
vated in the past but not this cycle) (5.7 ±3.73, n=859)
(p<0.01) (Fig. 3c), suggesting that current FSH is of con-
tinued relevance.
Because there were too few patients with elevated
PMax FSH and multiple completed cycles, MII count
was modeled using only the cycle-specific parameters
of age group, cycle number and stimulation type
(n=502 cycles in 353 patients). Age group (p<0.01),
cycle number (p<0.05) and stimulation type (p<0.001)
were significantly associated with MII count in a
multivariate model. Max FSH elevation above 13 was
not significantly associated with MII count (p=0.29)
after controlling for age group, cycle number and
stimulation type. However, current FSH remained as-
sociated with MII count (p<0.05). The combined




þ 0:028 MII Count Prevþ 0:079
Þ−0:009  CurrentFSH mIU=mLð Þ
log MII countð Þ ¼ 2:13−
(
0 if ≤35 yo
0:30 if 35; 38½ Þ yo
0:27 if 38; 41½ Þ yo
0:40 if 41; 43½ Þ yo
0:50 if > 43 yo
þ
(
0 if cycle 1
0:12 if cycle 2
0:23 if cycle 3
0:33 if cycle 4
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PMax FSH >13 (39.7 yo, antagonist cycle, cycle 1) whose
current FSH is 8 mIU/mL is predicted to obtain 5.7 MII
oocytes in her cycle on average versus 5.2 MII oocytes if
her current FSH were 14 mIU/mL. The resolution of an
elevated basal FSH back to normal in a subsequent cycle
is predicted to improve VOR counts by approximately
0.5 oocytes on average.Multiple clinical parameters are individually associated
with pregnancy and live birth rates
The individual (univariate) association of cycle parame-
ters with PR, clinical PR and LBR was explored with a
GEE model controlling for patient and cycle number
(Table 4). Age group, stimulation protocol, previous MII
count, current and previous E2 surge level, current and
previous total gonadotropin dose, AMH, transfer day
and number of embryos transferred were all individually
associated with pregnancy and birth rates (Table 4). In
contrast, IVF cycle number and insemination type (con-
ventional insemination vs ICSI) were not. Current, Max
and PMax FSH were all individually associated with clin-
ical outcomes (Table 4).FSH is associated with pregnancy rates in a combined
model
Clinical outcomes were modeled on the entire cohort of
embryo transfers (n=3407 cycles) in a combined (multi-
variate) model. Age group, number of embryos trans-
ferred and day of ET were associated with PR (p<0.001).
Stimulation type and cycle number were not signifi-
cantly associated with PR. After controlling for these
parameters, current FSH but not Max FSH remained
weakly associated with PR (OR 0.97 [0.95-0.99], p<0.05).
Similarly, only age group, number of embryos trans-
ferred and day of ET (all p<0.001) and current FSH (OR
0.97 [0.95–0.99], p<0.05) were associated with clinical
PR in a combined model. Age group, number of em-
bryos transferred and day of ET (all p<0.001) but not
stimulation type or cycle number were associated with
the LBR. Neither Max FSH nor current FSH were
associated with the LBR after controlling for these
parameters.Pregnancy and live birth rates not significantly improved
in cycles with elevated then improved FSH
To assess the clinical impact of the improved retrieval
outcomes observed in cycles with an elevated PMax
FSH and improved current FSH, we modeled PR, clin-
ical PR and LBRs using age group, number of embryos
transferred, day of ET and Max FSH and current FSH
in combination. When restricted to the patients with
PMax FSH >13 (n=502 transfers), age group, number of
embryos transferred and day of ET remained associated
with PR, clinical PR and LBRs (p<0.01). Neither Max
FSH nor current FSH were associated with PR, clinical
PR and LBRs after controlling for these parameters.Discussion
The study demonstrates that Max FSH predicts both
cycle cancellation and MII VOR outcomes better than
PMax or current FSH and confirms many existing find-
ings [4, 5, 11, 22–26]. This is the first study demonstrat-
ing that current FSH contributes to an assessment of
ovarian reserve after controlling for Max FSH. Given the
strong association of Max FSH with cancellation rates
and VOR outcomes, we advocate the calculation of Max
FSH with each cycle and its consideration hand in hand
with current FSH. Given the widespread validation of
AMH in ovarian reserve testing [33, 34], some clinicians
now argue for abandoning FSH altogether in favor of
AMH testing [26, 35–37]. However, many others con-
sider current FSH integral for clinical practice, particu-
larly in patients with suspected DOR [38]. The strong
connection between FSH and VOR outcomes in this
study after controlling for AMH also supports the con-
tinued assessment of FSH levels in addition to AMH.
Max FSH has multiple attributes that justify its adop-
tion as the primary FSH-based measure of ovarian re-
serve. Most significantly, Max FSH is more strongly
connected to VOR than PMax or current FSH, confirm-
ing previous findings [22–26]. By construction, Max
FSH values monotonically increase over time, paralleling
the presumed steady decline in ovarian reserve with age.
The relative stability of Max FSH versus current FSH ad-
dresses one of the key limitations of FSH-based ovarian
reserve assessment that has been used to argue against
it and in favor of AMH [37]. While the information
Table 4 Individual association of cycle parameters with pregnancy rate, clinical pregnancy rate and live birth rate
Pregnancy rate Clinical Pregnancy rate Live Birth rate
Parameter Compared
with
Odds ratio 95 % CI Sig. Odds ratio 95 % CI Sig. Odds ratio 95 % CI Sig.
Age Group B Age Group A 0.79 [0.65,0.96] * 0.81 [0.67,0.97] * 0.81 [0.67,0.99] *
Age Group C Age Group A 0.58 [0.48,0.70] *** 0.54 [0.45,0.65] *** 0.46 [0.38,0.56] ***
Age Group D Age Group A 0.46 [0.37,0.57] *** 0.37 [0.30,0.46] *** 0.31 [0.24,0.39] ***










0.75 [0.64,0.89] ** 0.73 [0.61,0.87] *** 0.73 [0.60,0.89] **
IVF Cycle 2 IVF Cycle 1 0.87 [0.75,1.00] 0.90 [0.78,1.04] 0.91 [0.78,1.07]
IVF Cycle 3 IVF Cycle 1 0.91 [0.73,1.13] 0.88 [0.70,1.10] 0.81 [0.63,1.03]
IVF Cycle 4 IVF Cycle 1 0.81 [0.57,1.13] 0.71 [0.50,1.01] 0.57 [0.39,0.85] **
IVF Cycle 5+ IVF Cycle 1 0.82 [0.54,1.24] 0.73 [0.48,1.11] 0.68 [0.41,1.13]
Previous MII Count Per Oocyte 1.04 [1.02,1.07] *** 1.05 [1.03,1.07] *** 1.03 [1.01,1.05] **
E2 Surge Level Per 1000 pg/
mL





1.16 [1.03,1.31] * 1.20 [1.06,1.36] ** 1.11 [0.98,1.27]
Total Gonadotropin
Dosage
Per 1000 IU 0.79 [0.75,0.83] *** 0.76 [0.72,0.80] *** 0.76 [0.71,0.80] ***
Previous Total
Gonadotropin Dosage
Per 1000 IU 0.89 [0.82,0.96] ** 0.82 [0.75,0.89] *** 0.81 [0.74,0.89] ***
AMH Per 1 ng/mL 1.14 [1.04,1.26] ** 1.15 [1.05,1.26] ** 1.08 [0.99,1.17]
Day 5 Transfer Day 3 Transfer 1.58 [1.36,1.84] *** 1.70 [1.47,1.97] *** 1.75 [1.50,2.03] ***
Day 6 Transfer Day 3 Transfer 1.57 [1.04,2.38] * 1.58 [1.06,2.36] * 1.67 [1.11,2.50] *
2 Embryos Transferred 1 Embryo
Transferred
2.41 [1.97,2.94] *** 2.49 [2.02,3.06] *** 2.46 [1.97,3.06] ***
3 Embryos Transferred 1 Embryo
Transferred
2.60 [2.08,3.24] *** 2.41 [1.92,3.02] *** 2.01 [1.59,2.56] ***
4 Embryos Transferred 1 Embryo
Transferred
2.02 [1.55,2.64] *** 2.03 [1.55,2.66] *** 1.97 [1.49,2.61] ***
5+ Embryos Transferred 1 Embryo
Transferred
2.56 [1.88,3.49] *** 2.05 [1.50,2.81] *** 1.71 [1.24,2.35] ***
ICSI Conventional
IVF
0.95 [0.83,1.09] 1.00 [0.87,1.15] 1.11 [0.96,1.28]
Max FSH Per 1 mIU/mL 0.93 [0.91,0.95] *** 0.93 [0.91,0.95] *** 0.94 [0.92,0.96] ***
PMax FSH Per 1 mIU/mL 0.93 [0.92,0.95] *** 0.93 [0.91,0.95] *** 0.94 [0.92,0.96] ***
Current FSH Per 1 mIU/mL 0.94 [0.92,0.96] *** 0.94 [0.92,0.96] *** 0.95 [0.93,0.97] ***
Max FSH Observed
1 Month Ago
0 Months Ago 1.28 [1.06,1.54] * 1.31 [1.08,1.58] ** 1.18 [0.97,1.45]
Max FSH Observed
2 Months Ago
0 Months Ago 1.01 [0.79,1.30] 0.93 [0.72,1.20] 0.87 [0.66,1.15]
Max FSH Observed 2-6
Months Ago
0 Months Ago 0.99 [0.82,1.20] 1.00 [0.83,1.21] 0.93 [0.76,1.14]
Max FSH Observed >6
Months Ago
0 Months Ago 1.12 [0.93,1.35] 1.20 [0.99,1.44] 1.10 [0.91,1.35]
A GEE model controlling for patient and cycle number was constructed to test the association of multiple clinical parameters with pregnancy rate, clinical pregnancy
rate or live birth rate. Association was noted as odds ratio (OR) with 95 % confidence intervals. Model significance was noted as ***(p<0.001), **(p<0.01) or *(p<0.05)
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plementary to AMH studies, further work is needed to
understand how to best combine Max FSH with other
ovarian reserve measures and integrate it into routine
clinical practice.
Since Max FSH will increase with repeated measure-
ments, patients who undergo additional treatment in-
cluding FSH measurements will have a higher Max FSH
than less frequently measured ones. However, it is un-
likely that higher Max FSH levels in patients with poor
VOR outcomes can be explained entirely by having
undergone more FSH measurements.
The exclusion of all FSH measurements with a same-
day E2 ≥100 pg/mL was performed in order to ensure a
reliable set of basal early follicular phase FSH measure-
ments and to remove the majority of measurements in-
appropriately labeled as being within in the early follicular
phase. These criteria functionally excluded patients under-
going an estrogen priming protocol, during which an other-
wise elevated basal FSH would have been falsely masked.
Of note, E2 levels are consistently <100 pg/mL in healthy
patients between D2 and D5 of their cycles and are com-
monly elevated at later stages of their menstrual cycle [39].
In addition, cycles with a (non-spurious) basal E2 level
≥100 pg/mL are known to have high cancellation rates and
poor clinical outcomes [40, 41]. Thus, exclusion of such
measurements focuses on the cycles whose outcomes are
difficult to predict and not already likely to be cancelled or
unsuccessful.
Our ability to estimate the time of infertility was limited
by the lack of detailed patient data prior to presentation.
While the first IVF cycle was initiated approximately
6 months following an initial non-IVF cycle at our clinic,
an infertility patient is not typically evaluated in our prac-
tice until she has failed to conceive for at least one year.
Thus, total time of infertility before initiating IVF is likely
greater than 18 months on average.
As an optimal ovarian hyperstimulation protocol for pa-
tients with poor ovarian response has yet to be defined
[42], cycle cancellations are often subject to physician
preference. Cancellations especially relied on clinician
judgment in determining suboptimal ovarian response.
The high cancellation rate observed in patients with an
elevated FSH and a poor expected ovarian response is un-
surprising. However, it is possible that a subset of patients,
particularly those with a low Max FSH, may benefit from
continuing their IVF cycles until retrieval.
While Max FSH is strikingly more associated with
VOR outcomes than current FSH, current cycle FSH is
far from irrelevant: the resolution of current FSH from
high to normal conveys approximately 0.5 additional
MII-stage oocytes of benefit. Thus, we find new evidence
to contradict existing dogma that a patient's ovarian re-
sponse entirely depends on her highest FSH.Given the particular VOR benefit observed in cycles
performed in the month following a Max FSH measure-
ment (Table 3), clinicians seeking to optimize VOR by
waiting for a lower basal FSH should be willing to con-
sider waiting at least one month following a new Max
FSH measurement. The basal FSH in the cycle following
an elevated Max FSH was lower than the previous cycle
basal FSH in 173 of 306 cycles (57 %), suggesting that in
the short term it is practical to wait for a lower current
FSH. Future studies will determine whether particular
patient subsets are likely to experience greater VOR
benefits by waiting for a “better” month. Circulating
antibodies to a wide range of ovarian, adrenocortical,
steroidogenic or FSH-related antigens have been
associated with DOR [43–45]. Fluctuations in antibody
levels may provide one possible explanation for the
modestly improved VOR outcomes anticipated in some
delayed cycles.
However, the benefits in these patients during a hypo-
thetically more favorable month are limited and must be
carefully weighed against their costs. In patients who are
able to undergo a limited number of IVF cycles (e.g. due
to age, time availability, insurance considerations, etc.),
even modestly improved MII oocyte VOR outcomes could
justify a delay in stimulation.
Alternatively, in patients with DOR who have a limited
number of months of remaining follicular function, lost
opportunities for prompt and successful VORs (e.g. in
patients in their 40s, with a history of particularly poor
outcomes, or an unforeseen requirement for chemother-
apy) may justify continued IVF treatment even with the
knowledge that VOR counts would be more advanta-
geous in cycles with lower current FSH.
The study failed to demonstrate an improvement in
pregnancy, clinical pregnancy or live birth rates for any
fluctuations in either Max FSH or current FSH in pa-
tients with an elevated PMax FSH. However, Max FSH
and current FSH significantly impacted pregnancy and
clinical pregnancy rates in the larger cohort. Despite the
large original patient cohort, the analysis of particular
subsets, e.g. those with AMH measurements, those with
elevated PMax FSH, those with multiple IVF cycles per-
formed only at our facility, was frequently impeded by
the small patient number. A larger study with improved
power may ultimately detect an improvement of LBR in
cycles with an improved Max FSH or current FSH after
controlling for a multiple clinical parameters. Such a study
would be crucial to support the existence of clinical, rather
than just embryological, benefits of cycle delay. Alterna-
tively, it is possible that the hypothetical "extra" oocyte re-
trieved because of improved current FSH was of
consistently lower quality than the others that would have
been retrieved otherwise and was consistently incapable of
sustaining a pregnancy.
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FSH must include consideration of all interventions to
improve the total mature oocyte yield. The stimulation
protocols for such patients should be tailored to account
for their expected poorer VOR outcome. In general, a
down regulation protocol with GnRH agonist risks over-
suppression of ovarian function, favoring use of a GnRH
antagonist protocol, preferably combined with estrogen
priming to prevent asynchronous follicle growth [46–51].
However, a meta-analysis associating antagonist protocols
with decreased VOR but comparable cancellation and
pregnancy rates compared with agonist protocols suggests
that agonist protocols might be preferable [52]. Egg bank-
ing with multiple stimulation-retrieval cycles can address
the poor VOR outcomes per cycle and facilitate retrieval
of a desired number of mature oocytes prior to embryo
transfer. Preimplantation genetic screening and selective
transfer of euploid embryos should be strongly considered
in order to avoid riskier multiple pregnancies or delays in
reproductive potential from pregnancies by aneuploid em-
bryos. Hence, although further research is necessary
to corroborate our findings, a delay in IVF cycle until a
"better" month likely conveys a limited improvement in
embryologic and possibly clinical reproductive outcome.
Decisions to delay cycles are best made in the context of a
couple’s detailed fertility history and reproductive goals.Conclusions
Max FSH predicts both cycle cancellation and MII VOR
outcomes better than PMax or current FSH. In patients
with previously elevated basal FSH (PMax >13 mIU/
mL), a lower current FSH remains associated with
slightly improved MII VOR even after controlling for
Max FSH. This improvement is not associated with a de-
tectably improved pregnancy or live birth rate.Additional file
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without a history of FSH elevation. Cycle data were categorized by presence
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noted. P-value comparisons were calculated between the elevated and
non-elevated groups by t-test. Significance was noted as *** (p<0.001),
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